Cara Therapeutics | CARA - Sales Revenues


Cara Therapeutics reported $2.57M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Chugai Pharma JPY 321.75B 24.55B Mar/2026
Cipla INR 65.41B 9.77B Mar/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
J&J USD 24.1B 500M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
RedHill Biopharma USD 1.29M 722K Jun/2024
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024